Investment analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Rating) in a research note issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright restated a “neutral” rating and issued a $8.00 price target on shares of Minerva Neurosciences in a research note on Thursday, March 9th.
Minerva Neurosciences Trading Up 3.1 %
NASDAQ NERV opened at $6.63 on Monday. Minerva Neurosciences has a 1-year low of $1.26 and a 1-year high of $15.27. The stock’s 50 day moving average is $4.16 and its two-hundred day moving average is $3.02. The company has a market capitalization of $36.93 million, a price-to-earnings ratio of -1.21 and a beta of 0.02.
Insiders Place Their Bets
In related news, President Geoff Race sold 22,082 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $3.85, for a total transaction of $85,015.70. Following the completion of the transaction, the president now directly owns 51,324 shares in the company, valued at $197,597.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Minerva Neurosciences news, President Geoff Race sold 22,082 shares of Minerva Neurosciences stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $3.85, for a total transaction of $85,015.70. Following the completion of the sale, the president now owns 51,324 shares of the company’s stock, valued at $197,597.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Remy Luthringer sold 23,753 shares of the company’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $3.85, for a total value of $91,449.05. Following the completion of the transaction, the chief executive officer now owns 72,635 shares of the company’s stock, valued at $279,644.75. The disclosure for this sale can be found here. Insiders sold a total of 49,415 shares of company stock worth $192,503 in the last quarter. 5.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of NERV. UBS Group AG boosted its position in Minerva Neurosciences by 914.5% during the 3rd quarter. UBS Group AG now owns 5,732 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 5,167 shares during the period. Renaissance Technologies LLC raised its stake in shares of Minerva Neurosciences by 185.9% during the third quarter. Renaissance Technologies LLC now owns 101,800 shares of the biopharmaceutical company’s stock valued at $940,000 after acquiring an additional 66,189 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Minerva Neurosciences during the third quarter worth about $231,000. Finally, BlackRock Inc. boosted its holdings in shares of Minerva Neurosciences by 54.7% during the third quarter. BlackRock Inc. now owns 78,086 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 27,612 shares during the period. Hedge funds and other institutional investors own 38.00% of the company’s stock.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Minerva Neurosciences (NERV)
- MarketBeat Week in Review – 5/29 – 6/2
- Trading Channel Breakout in Lululemon Brought by Earnings
- What Should Investors Make of These 3 Dividend Cuts?
- Constellation Brands Taps into Growth: Analysts Bullish on Stock
- CrowdStrike: Another Tech Stock to Buy on the Dip
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
